Respondent treatment characteristics.

Respondent treatment characteristics.</p

Respondent characteristics.

Respondent characteristics.</p

Effect sizes of differences in HRQoL/treatment satisfaction scores at the group level.

CLL = Chronic Lymphocytic Leukemia; CTSQ = Cancer Therapy Satisfaction Questionnaire; FACIT = Functional Assessment of Chronic Illness Therapy; FACT = Functional Assessment of Cancer Therapy; Ibr = Ibrutinib; Leu = Leukemia; MCS = Mental Component Summary; PCS = Physical Component Summary; SF-12v2 = Short Form-12v2® Health Survey. An effect size of 0.2 is considered a small effect, 0.5 is a medium effect, and 0.8 is a large effect. The sign of the effect indicates the direction of the effect. [Cohen 1988].</p

Effect sizes of differences in HRQoL/treatment satisfaction scores for total Ibrutinib group compared to norming groups.

CLL = Chronic Lymphocytic Leukemia; CTSQ = Cancer Therapy Satisfaction Questionnaire; FACIT = Functional Assessment of Chronic Illness Therapy; FACT = Functional Assessment of Cancer Therapy; Ibr = Ibrutinib; Leu = Leukemia; MCS = Mental Component Summary; PCS = Physical Component Summary; SF-12v2 = Short Form-12v2® Health Survey. An effect size of 0.2 is considered a small effect, 0.5 is a medium effect, and 0.8 is a large effect. The sign of the effect indicates the direction of the effect. [Cohen 1988].</p

Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) subscales at the group level, mean ± SD.

CLL = Chronic Lymphocytic Leukemia; EWB = Emotional Well-Being; FWB = Functional Well-Being; Ibr = Ibrutinib; Leu = Leukemia Subscale; PWB = Physical Well-Being; SWB = Social/Family Well-Being; Tx = Treatment. PWB score range: 0–28; SWB score range: 0–28; EWB score range: 0–24; FWB score range: 0–28; Leukemia Subscale score range: 0–68. Higher scores representing better outcomes. All comparisons of the CLL Ibrutinib groups to the CLL Norming Study 1L and 2L+ groups had p-vales <0.05.</p

Short Form-12v2^® Health Survey (SF-12v2) at the group level, mean ± SD.

CLL = Chronic Lymphocytic Leukemia; Ibr = Ibrutinib; MCS = Mental Component Summary; PCS = Physical Component Summary; Tx = Treatment. PCS score range: 0–80; MCS score range: 0–80. Higher scores representing better outcomes. All comparisons of the CLL Ibrutinib groups to the CLL Norming Study 1L and 2L+ groups had p-vales <0.05.</p

Functional Assessment of Cancer Therapy-General (FACT-G) total score at the group level, mean ± SD.

CLL = Chronic Lymphocytic Leukemia; Ibr = Ibrutinib; Tx = Treatment. FACT-G total score range: 0–108. Higher scores representing better outcomes. All comparisons of the CLL Ibrutinib groups to the CLL Norming Study 1L and 2L+ groups had p-vales <0.05.</p

Functional Assessment of Chronic Illness Therapy (FACIT)—Fatigue at the group level, mean ± SD.

CLL = Chronic Lymphocytic Leukemia; Ibr = Ibrutinib; Tx = Treatment. FACIT-Fatigue score range: 0–52. Higher scores representing better outcomes. All comparisons of the CLL Ibrutinib groups to the CLL Norming Study 1L and 2L+ groups had p-vales <0.05.</p

Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) total score at the group level, mean ± SD.

CLL = Chronic Lymphocytic Leukemia; Ibr = Ibrutinib; Tx = Treatment. FACT-Leu total score range: 0–176. Higher scores representing better outcomes. All comparisons of the CLL Ibrutinib groups to the CLL Norming Study 1L and 2L+ groups had p-vales <0.05.</p

Cancer Therapy Satisfaction Questionnaire (CTSQ) at the group level, mean ± SD.

CLL = Chronic Lymphocytic Leukemia; Ibr = Ibrutinib; Tx = Treatment;. Expectations of Therapy score range: 0–100; Feelings about Side Effects score range: 0–100; Satisfaction with Therapy score range: 0–100. Higher scores representing better outcomes. All comparisons of the CLL Ibrutinib groups to the CLL Norming Study 1L and 2L+ groups had p-vales <0.05.</p